Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersMatuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationAntibodies specifically targeting a locally misfolded region of tumor associated EGFRIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAInsights into the evolution of the ErbB receptor family and their ligands from sequence analysisInternalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Development of an EGFRvIII specific recombinant antibodyHighly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Discovery of internalizing antibodies to tumor antigens from phage libraries.High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIIThe contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerTherapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsRadioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsTargeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalizationTargeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFRA bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.Epidermal growth factor receptor targeting and challenges in glioblastoma.Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.Interaction of antibodies with ErbB receptor extracellular regions.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Emerging antibody combinations in oncology.Targeted therapy in head and neck cancer.Imaging EGFR and HER2 by PET and SPECT: a review.Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.MR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model.Ligand binding induces a conformational change in epidermal growth factor receptor dimers.Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.A novel magneto-fluorescent nano-bioprobe for cancer cell targeting, imaging and collection.A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.mAb806 binding to epidermal growth factor receptor: a computational study.RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
P2860
Q26751473-50D708DE-DA75-4121-9EE9-15CCFD4EA9DEQ27650259-C53D76D1-4F98-4594-848E-AA012091C15EQ27654155-C8154021-D1BF-4370-A104-15F1A758D7BDQ28660580-1636EB38-785E-4C1D-AB37-A273371D45A2Q28767062-D6AF9171-FF27-4F38-9B61-0470FF565806Q30480832-35484E02-B487-49DD-A569-1DF77AD1DC7EQ33711627-A1179AD0-23F3-4A0D-98F3-8C5C7879F50EQ33721106-89AE76B7-F2D3-4819-9684-315554101AD4Q34114794-D556EBBF-877D-4A3B-BD10-78A81B554208Q34421055-62169ED6-A292-402F-9575-8036C5A4851AQ34568677-9A6D5C8D-3CAA-4F70-A19C-FF06B52D8F0AQ34622547-F392FB52-D910-430B-97E7-3525C18696C6Q35589285-792E68E6-1F6F-435B-8DBD-3DC0F9E6E9BBQ35652789-D4E14A28-25A6-4846-B808-CFBD8EDAE9C1Q35659088-0D5E7FA3-5A14-4B98-94E2-2074B2AB4D52Q35893456-FB1FEF4D-5DDE-4F1C-B831-168B6192A33CQ36468876-F8AAF492-0D4B-4C63-ADC0-A27B344A39A4Q36616502-C48710D3-2B61-419D-BA5A-C5A2AE48DB9EQ36843748-0EC8C641-F12E-4436-9D93-3B5E8463EB8EQ36977684-B40F37B8-C76E-4F35-8C12-E33FA690AEC3Q36995979-914E56C0-7776-481E-8BE2-40712371B8FDQ37132712-0E783C26-B299-4372-81CA-C37D46AB1DEFQ37320814-88BE3C64-E0CE-496C-B067-8C221E6CDEDBQ37485865-1465BABC-B49D-47F1-B13D-3ED329F030B2Q37893414-C79AB1B5-7B51-4A0B-8D4E-E5F931126071Q37988981-56129844-5FA0-48A7-A672-81F6A40BC6F6Q38137829-A6A75DDD-7DA7-4C67-9F60-47E8FDF539F8Q38778443-91C17777-497F-4BBA-8319-4469444E6E93Q38832105-4502AB24-340D-4547-81D6-CC78FD562759Q39108385-9B795ADA-3F1A-4044-BAE8-B8112DA10F4DQ39144294-423E5807-F511-4894-B82F-EFB09BC57FD9Q39242623-A49D8125-AD04-44AD-A3D6-7A9E06044EB5Q39515308-76B2E878-3079-41ED-B987-0E02080C6373Q39552974-CC0C2781-239E-4A07-A840-B5D5A2E0A2F9Q39643088-FBAEE310-0A22-44D9-B59A-12B71C83E9EDQ39866142-63DA1CE9-BEEC-44A4-8734-5D2D868ACA82Q41022992-34624A7C-9DDF-494A-8135-1348AED9C92FQ47438165-A1C1EB6A-6701-44F7-ADB4-3E6A125F9E4FQ48465476-419C0195-C901-4D75-AE0D-AB474A0B2CE4Q57493689-9F824B0D-B060-4BDB-B085-F8C53CAB1960
P2860
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Identification of the epitope ...... tethered form of the receptor.
@en
type
label
Identification of the epitope ...... tethered form of the receptor.
@en
prefLabel
Identification of the epitope ...... tethered form of the receptor.
@en
P2093
P2860
P50
P356
P1476
Identification of the epitope ...... tethered form of the receptor.
@en
P2093
Achim A Jungbluth
Andrew M Scott
Antony W Burgess
Colin W Ward
Edouard C Nice
Francesca Walker
Gerd Ritter
Jennifer R Cochran
Julie Rothacker
K Dane Wittrup
P2860
P304
30375-30384
P356
10.1074/JBC.M401218200
P407
P577
2004-04-09T00:00:00Z